Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children. GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma maintenance therapy: improves long‑term control and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain or dyspepsia: occasional discomfort. - Cough: non‑productive. - Nasopharyngitis: mild cold‑like symptoms.

Serious or Rare Side Effects: - Mood changes: including agitation, depression or suicidal thoughts. - Allergic reactions: rash, urticaria or angioedema. - Hepatotoxicity: elevated liver enzymes. - Severe bronchospasm: paradoxical worsening of breathing. - Anaphylaxis: rare but life‑threatening hypersensitivity.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential exposure with a physician. - Hepatic impairment: monitor liver function in patients with known liver disease. - Concomitant asthma therapy: do not discontinue inhaled corticosteroids without medical advice. - Age restrictions: use according to approved pediatric dosing guidelines. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Phenobarbital or rifampin: may reduce montelukast plasma concentrations. - Strong CYP3A4 inducers: can lower therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR, monitor coagulation. - Antidepressants (SSRIs, SNRIs): monitor for mood changes. - Other leukotriene modifiers: avoid combined use due to overlapping toxicity.